(Q40159169)

18 September 2017

title

Amyloid imaging in vivo: implications for Alzheimer's disease management (English)

1 reference

18 September 2017

0 references

0 references

Nicolaas Plg Verhoeff

series ordinal

1

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Medical Diagnostics

18 September 2017

published in

1 reference

18 September 2017

volume

1

1 reference

18 September 2017

issue

3

1 reference

18 September 2017

page(s)

337-349

1 reference

Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Islington study of dementia subtypes in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

An overview on Primary Progressive Aphasia and its variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

The end of world population growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

The Topographical and Neuroanatomical Distribution of Neurofibrillary Tangles and Neuritic Plaques in the Cerebral Cortex of Patients with Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Frequency of stages of Alzheimer-related lesions in different age categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Phases of A beta-deposition in the human brain and its relevance for the development of AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Tau pathology in Alzheimer disease and other tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Radioligand development for PET imaging of beta-amyloid (Abeta)--current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Alzheimer's amyloid fibrils: structure and assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Amyloid, the presenilins and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Alternate aggregation pathways of the Alzheimer beta-amyloid peptide. An in vitro model of preamyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Neuropathologic features of amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Quantum dots: a quantum jump for molecular imaging?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Preventing blood contamination in nuclear pharmacies: lessons from an outbreak of hepatitis C virus infections and contaminated 99mTc-sestamibi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Neuroimaging of vessel amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

PET of brain amyloid and tau in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Comparison of manual and semi-automated delineation of regions of interest for radioligand PET imaging analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Therapeutic approaches to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Emerging therapeutics for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Acetylcholinergic neurotransmission and the beta-amyloid cascade: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Cerebral hemorrhage after passive anti-Abeta immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Cerebral amyloid deposition and diffuse plaques in "normal" aging: Evidence for presymptomatic and very mild Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17530059.1.3.337

21 January 2018

Identifiers

DOI

10.1517/17530059.1.3.337

1 reference

18 September 2017

1 reference